Share this story:

Ventripoint Signs an Authorized Sales Agent Agreement with Irudigi





Toronto, Ontario / TheNewswire / May 15, 2019 - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company", TSXV:VPT, OTCQB:VPTDF) is pleased to announce that they have signed an Authorized Sales Agent Agreement with Irudigi out of France.

"We are very excited to start working with the Ventripoint team and look forward to bringing their latest breakthroughs in cardiac imaging to France. France is a unique market, with a lack of MRI scanners, growing demand, and mounting pressure to reduce healthcare costs. Meanwhile, there are over 1 million people suffering from cardiac impairments in France, a number that grew by 30% over the last decade. The combination of low MRI coverage, a growing number of patients, and financial incentives make the Ventripoint VMS+ a perfectly suited solution for the French market" notes Pierre Zavattero, CEO of Irudigi.

When looking at data from statista.com for the number of magnetic resonance imaging (MRI) units in selected countries as of 2017 (per million population), there are 2.5 times more MRI scanners in Germany, and 2 times more in Spain and Italy than in France. Consequently, current waiting times for MRI are over a month in France, while they are only 1 to 2 weeks for echography, with a significantly shorter examination time.

"Irudigi's knowledge of the cardiac market in France and experience within the imaging industry will be an asset to the business as we continue to grow. They will build on current relationships and create new ones," commented Dr. George Adams, Ventripoint Diagnostics CEO.

About Ventripoint Diagnostics Ltd.

Ventripoint's technology is a leading Artificial Intelligence (AI) approach known as Knowledge-Based Reconstruction (KBR), used to create applications to monitor heart disease, a leading cause of death worldwide. The VMS+ is the first cost-effective and accurate AI tool for measuring whole heart function using conventional ultrasound. The Company has developed a suite of applications for all major heart diseases and is actively commercializing the approach to improve cardiac care.

For further information please contact:

Dr. George Adams, CEO, Telephone: (519) 803-6937

Email: gadams@ventripoint.com

Forward Looking Statements:

This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. The use of any of the words "expect", "anticipate", "continue", "estimate", "objective", "ongoing", "may", "will", "project", "should", "believe", "plans", "intends" and similar expressions are intended to identify forward-looking information or statements. The forward-looking statements and information are based on certain key expectations and assumptions made by the Corporation. Although the Corporation believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because the Corporation can give no assurance that they will prove to be correct. Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. Other factors, which could materially affect such forward-looking information are described in the risk factors in the Corporation's most recent annual management's discussion and analysis that is available on the Corporation's profile on SEDAR at www.sedar.com. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included in this news release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news release are made as of the date hereof and the Corporation undertakes no obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release